Johnson & Johnson's Phase 2b study for atopic dermatitis did not meet high-bar efficacy and was terminated early.
What's Going On With Johnson & Johnson Stock Friday?
Johnson & Johnson's Phase 2b study for atopic dermatitis did not meet high-bar efficacy and was terminated early.
